@article{67c6523563964e59943c7e344afb1a61,
title = "Editorial: bacterial gut symbionts as live biotherapeutic agents in IBS-a rosy future despite potential long-term safety concerns. Authors' reply",
keywords = "Humans, Irritable Bowel Syndrome/drug therapy, Bacteria",
author = "Quigley, {Eamonn M.M.} and Alex Stevenson and Ian Jeffery and Jacob Masters",
note = "Funding Information: Declaration of personal interests: EMMQ serves as a consultant to 4D Pharma, Atlantia Food Clinical Trials, Axon Pharma, Biocodex, Novozymes, Precisionbiotics, Salix and Vibrant and has received research support from 4D Pharma, Biomerica, Takeda and Vibrant.AS is an emloyee of 4D Pharma and owns stock and shares in 4D Pharma, IJ is an employee of 4D Pharma JM is an employee of 4D Pharma.",
year = "2023",
month = feb,
doi = "10.1111/apt.17354",
language = "English (US)",
volume = "57",
pages = "347--348",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley",
number = "3",
}